Inhalable nanoparticulate powders for respiratory delivery

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 5, 2015, Pages 1189-1199

  Muralidharan, Priya ^a   Malapit, Monica ^a   Mallory, Evan ^a   Hayes, Don ^b   Mansour, Heidi M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Dry powder inhaler; Inhalation powders; Lung nasal; Particle engineering design; Pulmonary nanomedicine; Solid state

Indexed keywords

CLINICAL RESEARCH; CONTROLLED DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; POWDERS;

DRUG DELIVERY SYSTEM; DRY POWDER INHALER; LUNG/NASAL; PARTICLE ENGINEERING; RESPIRATORY TRACT; TARGETED DELIVERY; TARGETED PULMONARY DELIVERIES; THERAPEUTIC EFFECTS;

TARGETED DRUG DELIVERY;

ANTHRAX VACCINE; AZITHROMYCIN; BUDESONIDE; CIPROFLOXACIN; DOXORUBICIN; IBUPROFEN; INDOMETACIN; INFLUENZA VACCINE; LACTOSE; NANOPARTICLE; PACLITAXEL; RECOMBINANT HUMAN INSULIN; SOLID LIPID NANOPARTICLE; TACROLIMUS; TOBRAMYCIN; TRANILAST; VACCINE; AEROSOL; LIPOSOME; POLYMER; POWDER;

ADSORPTION; DRY POWDER; DRY POWDER INHALER; FREEZE DRYING; HUMAN; INHALATION; MUCOADHESION; NONHUMAN; PARTICLE SIZE; REVIEW; SPRAY DRYING; THERAPY EFFECT; WETTABILITY; ADMINISTRATION AND DOSAGE; AEROSOL; ANIMAL; CHEMISTRY; DEVICES; DRUG DELIVERY SYSTEM; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LUNG; METABOLISM; POWDER; PROCEDURES;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; AEROSOLS; ANIMALS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; HUMANS; LIPOSOMES; LUNG; NANOPARTICLES; POLYMERS; POWDERS;

EID: 84931076834     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.01.007     Document Type: Review

References (92)

1. Mahmud A., Discher D.E. Lung vascular targeting through inhalation delivery: insight from filamentous viruses and other shapes. IUBMB Life 2011, 63(8):607-612.
2. Sung J.C., Pulliam B.L., Edwards D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007, 25(12):563-570.
3. Bhavane R., Karathanasis E., Annapragada A.V. Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery. J Control Release 2003, 93(1):15-28.
4. Thorley A.J., Tetley T.D. New perspectives in nanomedicine. Pharmacol Ther 2013, 140(2):176-185.
5. Pandey R., Khuller G.K. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005, 55(4):430-435.
6. Hickey A.J. Controlled delivery of inhaled therapeutic agents. J Control Release. 2014 Sep 28, 190:182-188.
7. Wu X., Zhang W., Hayes D., Mansour H.M. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery. Int J Nanomedicine 2013, 8:1269-1283.
8. Mansour H.M., Rhee Y.S., Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine 2009, 4:299-319.
9. Kannan R.M., Nance E., Kannan S., Tomalia D.A. Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications. J Intern Med 2014, 10.1111/joim.12280.
10. Wu X., Hayes D., Zwischenberger J.B., Kuhn R.J., Mansour H.M. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug Des Devel Ther 2013, 7:59-72.
11. Suarez S., Hickey A.J. Drug properties affecting aerosol behavior. Respir Care 2000, 45(6):652-666.
12. <601> aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers monograph. USP 29-NF 24 The United States Pharmacopoeia and The National Formulary: The Official Compendia of Standards 2006, vol. 29/24:2617-2636. The United States Pharmacopeial Convention, Inc, Rockville, MD.
13. Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005, 172(12):1497-1504.
14. Stahlhofen W., Gebhart J., Heyder J. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J 1980, 41(6):385-398a.
15. Murray J.F., Nadel J.A. Textbook of respiratory medicine 1988, Saunders, Philadelphia.
16. Raabe O.G. Comparison of the criteria for sampling 'inhalable' and 'respirable' aerosols. Ann Occup Hyg 1982, 26(1-4):33-45.
17. Telko M.J., Hickey A.J. Dry powder inhaler formulation. Respiratory care Sep 2005, 50(9):1209-1227.
18. Hadinoto K., Phanapavudhikul P., Kewu Z., Tan R.B. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int J Pharm 2007, 333(1-2):187-198.
19. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009, 61(2):158-171.
20. Cheow W.S., Chang M.W., Hadinoto K. Antibacterial efficacy of inhalable antibiotic-encapsulated biodegradable polymeric nanoparticles against E. coli biofilm cells. J Biomed Nanotechnol 2010, 6(4):391-403.
21. Meenach S.A., Vogt F.G., Anderson K.W., Hilt J.Z., McGarry R.C., Mansour H.M. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomedicine 2013, 8:275-293.
22. Velasquez L.S., Shira S., Berta A.N., et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 2011, 29(32):5221-5231.
23. Ishikawa F., Murano M., Hiraishi M., Yamaguchi T., Tamai I., Tsuji A. Insoluble powder formulation as an effective nasal drug delivery system. Pharm Res 2002, 19(8):1097-1104.
24. Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?. J Pharm Sci 2007, 96(3):473-483.
25. Vila A., Sanchez A., Evora C., Soriano I., McCallion O., Alonso M.J. PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm 2005, 292(1-2):43-52.
26. Chen K.H., Di Sabatino M., Albertini B., Passerini N., Kett V.L. The effect of polymer coatings on physicochemical properties of spray-dried liposomes for nasal delivery of BSA. Eur J Pharm Sci 2013, 50(3-4):312-322.
27. Dehghan S., Tavassoti Kheiri M., Tabatabaiean M., Darzi S., Tafaghodi M. Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization. Arch Pharm Res 2013, 36(8):981-992.
28. Wang S.H., Kirwan S.M., Abraham S.N., Staats H.F., Hickey A.J. Stable dry powder formulation for nasal delivery of anthrax vaccine. J Pharm Sci 2012, 101(1):31-47.
29. Wu X., Adedoyin O.O., Mansour H.M. Pulmonary and nasal anti-inflammatory and anti-allergy inhalation aerosol delivery systems. Anti-Inflammatory Anti-Allergy Agents Med Chem 2011, 215-229.
30. Hickey A.J., Mansour H.M. Delivery of drugs by the pulmonary route. Modern Pharmaceutics 2009, 191-219. Taylor & Francis, New York. A.T. Florence, J. Siepmann (Eds.).
31. Hickey A.J., Mansour H.M. Formulation challenges of powders for the delivery of small molecular weight molecules as aerosols. Modified-release drug delivery technology vol 2 2008, 573-602. Informa Healthcare, New York. M.J. Rathbone, M.S. Roberts, M.E. Lane (Eds.).
32. Hickey A.J., Mansour H.M., Martin J.T., et al. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci 2007, 96(5):1282-1301.
33. Hickey A.J., Mansour H.M., Telko M.J., et al. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics. J Pharm Sci 2007, 96(5):1302-1319.
34. Hugh D.C., Smyth A.J.H. Controlled pulmonary drug delivery 2011, Springer.
35. Li X., Vogt F.G., Hayes D., Mansour H.M. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers. J Aerosol Med Pulm Drug Deliv Apr 2014, 27(2):81-93.
36. Rahimpour Y., Kouhsoltani M., Hamishehkar H. Alternative carriers in dry powder inhaler formulations. Drug Discov Today May 2014, 19(5):618-626.
37. Bailey M.M., Berkland C.J. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev Jan 2009, 29(1):196-212.
38. Al-Hallak M.H., Sarfraz M.K., Azarmi S., Roa W.H., Finlay W.H., Lobenberg R. Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. Ther Deliv Oct 2011, 2(10):1313-1324.
39. Menon J.U., Ravikumar P., Pise A., Gyawali D., Hsia C.C., Nguyen K.T. Polymeric nanoparticles for pulmonary protein and DNA delivery. Acta biomaterialia Jun 2014, 10(6):2643-2652.
40. Kling J. Sanofi to propel inhalable insulin Afrezza into market. Nat Biotechnol 2014, 32(9):851-852. [09//print].
41. Xu Z., Mansour H.M., Hickey A.J. Particle interactions in dry powder inhaler unit processes: a review. J Adhes Sci Technol 2012, 451-482.
42. Roa W.H., Azarmi S., Al-Hallak M.H., Finlay W.H., Magliocco A.M., Lobenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release 2011, 150(1):49-55.
43. Kumar A., Mansour H.M., Friedman A., Blough E.R. Nanomedicine in drug delivery 2013, CRC Press.
44. Chow A.H., Tong H.H., Chattopadhyay P., Shekunov B.Y. Particle engineering for pulmonary drug delivery. Pharm Res Mar 2007, 24(3):411-437.
45. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010, 49(36):6288-6308.
46. Vonarbourg A., Passirani C., Saulnier P., Simard P., Leroux J.C., Benoit J.P. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A 2006, 78(3):620-628.
47. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2(3):214-221.
48. Chung H.A., Kato K., Itoh C., Ohhashi S., Nagamune T. Casual cell surface remodeling using biocompatible lipid-poly(ethylene glycol)(n): development of stealth cells and monitoring of cell membrane behavior in serum-supplemented conditions. J Biomed Mater Res A 2004, 70A(2):179-185.
49. Nag O.K., Awasthi V. Surface engineering of liposomes for stealth behavior. Pharmaceutics 2013, 5(4):542-569.
50. Youn Y.S., Kwon M.J., Na D.H., Chae S.Y., Lee S., Lee K.C. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. J Control Release 2008, 125(1):68-75.
51. Edwards D.A., Hanes J., Caponetti G., et al. Large porous particles for pulmonary drug delivery. Science 1997, 276(5320):1868-1871.
52. Muralidharan P., Mallory E., Malapit M., Hayes D., Mansour H.M. Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers. Pharmaceutics 2014, 6(2):333-353.
53. Chougule M., Padhi B., Misra A. Development of spray dried liposomal dry powder inhaler of Dapsone. AAPS PharmSciTech 2008, 9(1):47-53.
54. Kaye R.S., Purewal T.S., Alpar H.O. Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies. J Pharm Sci 2009, 98(11):4055-4068.
55. Wang G., Yu B., Wu Y., Huang B., Yuan Y., Liu C.S. Controlled preparation and antitumor efficacy of vitamin E TPGS-functionalized PLGA nanoparticles for delivery of paclitaxel. Int J Pharm 2013, 446(1-2):24-33.
56. Jensen D.K., Jensen L.B., Koocheki S., et al. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Control Release 2012, 157(1):141-148.
57. Yang M., Yamamoto H., Kurashima H., et al. Design and evaluation of poly(DL-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation. Eur J Pharm Sci 2012, 46(5):374-380.
58. Wang H., Wu Y., Zhao R., Nie G. Engineering the assemblies of biomaterial nanocarriers for delivery of multiple theranostic agents with enhanced antitumor efficacy. Adv Mater 2013, 25(11):1616-1622.
59. Yang Y., Cheow W.S., Hadinoto K. Dry powder inhaler formulation of lipid-polymer hybrid nanoparticles via electrostatically-driven nanoparticle assembly onto microscale carrier particles. Int J Pharm 2012, 434(1-2):49-58.
60. Al-Hallak M.H., Sarfraz M.K., Azarmi S., et al. Distribution of effervescent inhalable nanoparticles after pulmonary delivery: an in vivo study. Ther Deliv 2012, 3(6):725-734.
61. Azarmi S., Lobenberg R., Roa W.H., Tai S., Finlay W.H. Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles. Drug Dev Ind Pharm 2008, 34(9):943-947.
62. Ely L., Roa W., Finlay W.H., Lobenberg R. Effervescent dry powder for respiratory drug delivery. Eur J Pharm Biopharm 2007, 65(3):346-353.
63. Michael J., Rathbone J.H., Roberts M.S., Lane M.E. Modified-release drug delivery technology. vol. 2 2008, Informa healthcare USA, Inc, New york, NY. 2 ed.
64. Li X., Vogt F.G., Hayes D., Mansour H.M. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers. J Aerosol Med Pulm Drug Deliv 2014, 27(2):81-93.
65. Tomoda K., Ohkoshi T., Hirota K., et al. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf B: Biointerfaces 2009, 71(2):177-182.
66. Li X., Vogt F.G., Hayes D., Mansour H.M. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery. Eur J Pharm Sci 2014, 52:191-205.
67. Park C.W., Li X., Vogt F.G., et al. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int J Pharm 2013, 455(1-2):374-392.
68. Meenach S.A., Anderson K.W., Zach Hilt J., McGarry R.C., Mansour H.M. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci 2013, 49(4):699-711.
69. Tomoda K., Ohkoshi T., Kawai Y., Nishiwaki M., Nakajima T., Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles. Colloids Surf B: Biointerfaces 2008, 61(2):138-144.
70. Cheow W.S., Ng M.L., Kho K., Hadinoto K. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants. Int J Pharm 2011, 404(1-2):289-300.
71. Wang Y., Kho K., Cheow W.S., Hadinoto K. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles. Int J Pharm 2012, 424(1-2):98-106.
72. Maa Y.F., Nguyen P.A., Sweeney T., Shire S.J., Hsu C.C. Protein inhalation powders: spray drying vs spray freeze drying. Pharm Res 1999, 16(2):249-254.
73. Onoue S., Aoki Y., Kawabata Y., et al. Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases. J Pharm Sci 2011, 100(2):622-633.
74. El-Gendy N., Selvam P., Soni P., Berkland C. Development of budesonide nanocluster dry powder aerosols: processing. J Pharm Sci 2012, 101(9):3425-3433.
75. Longest P.W., Hindle M. Condensational growth of combination drug-excipient submicrometer particles for targeted high efficiency pulmonary delivery: comparison of CFD predictions with experimental results. Pharm Res 2012, 29(3):707-721.
76. Duret C., Wauthoz N., Sebti T., Vanderbist F., Amighi K. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. Int J Nanomedicine 2012, 7:5475-5489.
77. Noymer P.D., Myers D.J., Cassella J.V., Timmons R. Assessing the temperature of thermally generated inhalation aerosols. J Aerosol Med Pulm Drug Deliv 2011, 24(1):11-15.
78. Myers D.J., Timmons R.D., Lu A.T., et al. The effect of film thickness on thermal aerosol generation. Pharm Res 2007, 24(2):336-342.
79. Shen X., Hindle M., Byron P.R. Effect of energy on propylene glycol aerosols using the capillary aerosol generator. Int J Pharm 2004, 275(1-2):249-258.
80. Onischuk A.A., Tolstikova T.G., Sorokina I.V., et al. Anti-inflammatory effect from indomethacin nanoparticles inhaled by male mice. J Aerosol Med Pulm Drug Deliv 2008, 21(3):231-243.
81. Onischuk A.A., Tolstikova T.G., Sorokina I.V., et al. Analgesic effect from Ibuprofen nanoparticles inhaled by male mice. J Aerosol Med Pulm Drug Deliv 2009, 22(3):245-253.
82. Kelly J.Y., DeSimone J.M. Shape-specific, monodisperse nano-molding of protein particles. J Am Chem Soc 2008, 130(16):5438-5439.
83. Fromen C.A., Shen T.W., Mack P., et al. Fabrication and characterization of engineered particles for respiratory drug delivery. J Aerosol Med Pulm Drug Deliv 2013, 26(4):A247. [A247].
84. Garcia A., Mack P., Williams S., et al. Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications. J Drug Deliv 2012, 2012(941243):10. 10.1155/2012/941243.
85. Yang M., Yamamoto H., Kurashima H., et al. Design and evaluation of inhalable chitosan-modified poly (DL-lactic-co-glycolic acid) nanocomposite particles. Eur J Pharm Sci 2012, 47(1):235-243.
86. El-Gendy N., Aillon K.L., Berkland C. Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. Int J Pharm 2010, 391(1-2):305-312.
87. Yamasaki K., Kwok P.C., Fukushige K., Prud'homme R.K., Chan H.K. Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int J Pharm 2011, 420(1):34-42.
88. Sung J.C., Padilla D.J., Garcia-Contreras L., et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009, 26(8):1847-1855.
89. Duan J., Vogt F.G., Li X., Hayes D., Mansour H.M. Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. Int J Nanomedicine 2013, 8:3489-3505.
90. Azarmi S., Tao X., Chen H., et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 2006, 319(1-2):155-161.
91. El-Gendy N., Pornputtapitak W., Berkland C. Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols. Eur J Pharm Sci 2011, 44(4):522-533.
92. Bhavna, Ahmad F.J., Mittal G., et al. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm 2009, 71(2):282-291.